Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PTC299 ((4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate) 是一种口服活性的 VEGFA mRNA 翻译抑制剂,可选择性地抑制转录后水平的 VEGF 蛋白合成。它还是二氢乳酸脱氢酶 (DHODH) 的有效抑制剂,可研究血液系统恶性肿瘤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 898 | 现货 | ||
5 mg | ¥ 2,530 | 现货 | ||
10 mg | ¥ 3,850 | 现货 | ||
25 mg | ¥ 6,190 | 现货 | ||
50 mg | ¥ 8,520 | 现货 | ||
100 mg | ¥ 11,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,590 | 现货 |
产品描述 | PTC299 ((4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate) is an orally active inhibitor of VEGFA mRNA translation and selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydrolactate dehydrogenase (DHODH). |
体外活性 | PTC299 as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors.?To guide precision cancer treatment, we performed extensive biological characterization of the activity of PTC299 and demonstrated that inhibition of VEGF production and cell proliferation by PTC299 is linked to a decrease in uridine nucleotides by targeting dihydroorotate dehydrogenase (DHODH), a rate-limiting enzyme for de novo pyrimidine nucleotide synthesis. |
别名 | Emvododstat, (4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate |
分子量 | 467.34 |
分子式 | C25H20Cl2N2O3 |
CAS No. | 1256565-36-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (106.99 mM), sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1398 mL | 10.6988 mL | 21.3977 mL | 53.4942 mL |
5 mM | 0.428 mL | 2.1398 mL | 4.2795 mL | 10.6988 mL | |
10 mM | 0.214 mL | 1.0699 mL | 2.1398 mL | 5.3494 mL | |
20 mM | 0.107 mL | 0.5349 mL | 1.0699 mL | 2.6747 mL | |
50 mM | 0.0428 mL | 0.214 mL | 0.428 mL | 1.0699 mL | |
100 mM | 0.0214 mL | 0.107 mL | 0.214 mL | 0.5349 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PTC299 1256565-36-2 Angiogenesis Metabolism Tyrosine Kinase/Adaptors Dehydrogenase VEGFR hematologic Vascular endothelial growth factor receptor cancer Inhibitor myelosuppression Emvododstat off-target DHODH DNA/RNA Synthesis Dihydroorotate Dehydrogenase PTC 299 kinase (4-chlorophenyl) (1S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate oral inhibit malignancies PTC-299 inhibitor